Summary of the electrophysiological actions of ET-1, FR139317 and STXS6c on IK, ICl(Ca), INS and IK(Ca)
| Aorta | Basilar IK | Pulmonary | |||||
|---|---|---|---|---|---|---|---|
| IK | ICl(Ca)/INS | IK(Ca) | IK | ICl(Ca) | IK(Ca) | ||
| ET-1 | Inhibition 38.3 ± 9.1% (n= 5) | Activation 451.3 ± 116.6 nA · ms (n = 5) | Enhancement (n = 5) | Inhibition 42.0 ± 8.5% (n = 6) | Inhibition 25.1 ± 4.1% (n = 6) | Activation 391.7 ± 117.3 nA · ms (n = 5) | Enhancement (n = 4) |
| ET-1 + FR139317 | Inhibition 22.0 ± 8.9% (n = 3) | Activation blocked 0.0 nA · ms (n = 3) | Enhancement blocked (n = 3) | Inhibition blocked 1.8 ± 1.8% (n = 4) | Inhibition 31.9 ± 1.9% (n = 5) | Activation blocked 97.5 ± 57.9 nA · ms (n = 5) | Enhancement blocked (n = 5) |
| STX S6c | Inhibition 21.6 ± 8.3% (n = 3) | No activation 0.0 nA · ms (n = 5) | No enhancement (n = 3) | No inhibition 3.9 ± 3.9% (n = 3) | Inhibition 28.5 ± 4.1% (n = 5) | No activation 0.0 nA · ms (n = 6) | No enhancement (n = 5) |
The effects of ET-1, in the absence and presence of FR139317 and STXS6c are summarized in this table. The effects are described both qualitatively and quantitatively in each case, except regarding the effects on IK(Ca) where only a qualitative assessment is presented.